Table of Contents
ISRN Dentistry
Volume 2012 (2012), Article ID 904963, 6 pages
Research Article

Biocompatibility of Intracanal Medications Based on Calcium Hydroxide

1Department of Restorative Dentistry, Araraquara Dental School, Universidade Estadual Paulista (UNESP), 14801-903 Araraquara, SP, Brazil
2Laboratory of Histology and Embryology, Department of Morphology, Araraquara Dental School, Universidade Estadual Paulista (UNESP), 14801-903 Araraquara, SP, Brazil

Received 6 November 2012; Accepted 27 November 2012

Academic Editors: H. S. Cardash, J. H. Jeng, and G. Mount

Copyright © 2012 Carolina Andolfatto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Objective. The aim of this study was to evaluate the rat subcutaneous tissue reaction to calcium hydroxide-based intracanal medicaments, UltraCal XS (calcium hydroxide, barium sulphate, aqueous matrix), Hydropast (calcium hydroxide, barium sulphate, and propyleneglycol), and Calen (Calcium hydroxide, zinc oxide, colophony, and polyethyleneglycol), used as a control. Methods. Forty-eight rats (Rattus Norvegicus Holtzman) were distributed in three groups: Calen, UltraCal XS, and Hydropast. Polyethylene tubes filled with one of the medicaments were implanted in the dorsal subcutaneous. After 7 and 30 days, the implants were removed and the specimens were fixed and embedded in paraffin. Morphological and quantitative analyses were carried out in the HE-stained sections. The numerical density of inflammatory cells in the capsule was evaluated and statistical analyses were performed ( ). Results. At 7 days, all materials induced an inflammatory reaction in the subcutaneous tissue adjacent to the implants. In all groups, a significant reduction in the number of inflammatory cells and giant cells was verified in the period of 30 days. Conclusion. These results indicate that the calcium hydroxide-based medicaments evaluated present biocompatibility similar to Calen.